Early data shows mRNA-4359 may benefit patients with advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.


http://dlvr.it/TDHDh8

Comments

Popular posts from this blog

GLP-1 Drugs Before Bariatric Surgery Can Help People With Extreme Obesity

Diagnostic stewardship approach to C. diff reduces unnecessary testing